Bio.dy/dx

Practical biostatistics for clinical development — adaptive design, Bayesian methods, early phase oncology, and IVDs, built on 13+ years of hands-on trial design and regulatory experience.
Published

March 13, 2026

Biostats insight, opinion and tools for clinical development.

Trial design, analysis, biomarkers, and simulation in R. By Paul Steven.

Practical insights in clinical trial design, complex endpoints, and biomarker-driven development — drawn from 13+ years across early phase oncology, rare disease, IVDs, and companion diagnostics.

Latest Insights

Article 30 Sep 26

Adventures in AI - Agentic Coding

New series: how agentic coding with Claude Code and OpenAI Codex has opened up my own research as a Biostatistician.

Read article →

Publication 18 Jun 26

Timing of Bronchoscopy and Plasma Microbial Cell-Free DNA Sequencing in Immunocompromised Host Pneumonia

Mourad A, Lupu DS, Richey M, Steven P, et al. Open Forum Infectious Diseases, 2026.

Read paper →

App 19 Mar 26

Adaptive Enrichment Explorer

Interactive R/Shiny app for simulating adaptive enrichment in biomarker-driven oncology trials.

Open Tools & Demos →

No matching items

View all articles →

Expertise

Trial Design

Bayesian adaptive designs for early phase trials — dose escalation (BOIN), dose optimisation (MATS), basket trials, and adaptive enrichment. IVD and analytical studies utilizing device endpoints.

Complex Endpoints

Non-standard and translational endpoints including PD, ctDNA, MRD, and analytical device output. Statistical strategy aligned with underlying science and regulatory expectations.

Simulation in SAS and R

Simulation frameworks for dose-response, biomarker thresholds, and design operating characteristics. R/Shiny tools for interactive exploration of Bayesian models.